Shots:

• Adaptive to expand its platform for selection of B cell receptors of recovered patients from COVID-19. Amgen will utilize its Ab engineering and drug development capabilities to select and develop Abs designed to bind and neutralize SARS-CoV-2. Additionally- Amgen‘s subsidiary DeCODE Genetics located in Iceland- will provide genetic information from patients infected with COVID-19
• The focus of the collaboration is to combine expertise to discover and develop fully human neutralizing Abs for SARS-CoV-2 virus to treat COVID-19 where Adaptive's immunological medicine platform will help in identification of virus neutralizing Abs
• Additionally- the Abs can be used to treat patients with COVID-19 and can be administered to patients with who are at increased risk of exposure to SARS-CoV-2

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image:  Amgen